Orphan Therapeutics Accelerator Announces Foundational Partnerships

Originally published on Business Wire BOSTON–(BUSINESS WIRE)–The Orphan Therapeutics Accelerator (OTXL), a non-profit biotech organization focused on completing development and commercializing therapies for ultra-rare conditions, today announced collaborative partnerships with rare disease-focused global biotech and pharmaceutical companies, a contract development and manufacturing organization (CDMO), contract research organization (CRO), and AI-based platform providers, establishing the foundation […]
Transformation in Trials

Rob Freistat, President of Uncommon Cures, discusses how clinical trials are transforming to accelerate drug development and ensure patients receive treatments faster, particularly in the rare disease space.
